Laila Hassanian Emara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Laila Hassanian Emara has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Abd El-Rahman El-Ashmawy
Medicinal and Pharmaceutical Chemistry Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Giza, Egypt
12 shared publications - Nesrin Fouad Taha
Jordan University of Science and Technology Faculty of Dentistry, Ibrid, Jordan
12 shared publications Nadia M. Mursi
Department of Pharmaceutics, Faculty of Pharmacy, Cairo University, Cairo, Egypt
8 shared publications- Ebtesam W. Elsayed
Medicinal and Pharmaceutical Chemistry Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, P.O.12622, 33 EL Bohouth St. (former EL Tahrir St.), Dokki, Giza, Egypt
4 shared publications - Maha F. Emam
Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland
4 shared publications Aya R. Abdou
Industrial Pharmacy Laboratory, Medical and Pharmaceutical Chemistry Department, Division of Pharmaceutical Industries, National Research Centre, El-Tahrir Street, Dokki, Giza 12622, Egypt
3 shared publications
Latest Publications
- Open Access
- 11 July 2025
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 20 (4) , 1-15
Promising Alginate-Gelatin Scaffolds Containing 5-Fluorouracil and Reinforced with Zinc-Modified Hydroxyapatite: Cell Attachment and One-Year Stability Study
Purpose: The current study evaluated the cell attachment capability and long-term stability of 5-fluorouracil (5-FU) loaded alginate-gelatin scaffolds reinforced with zinc-doped hydroxyapatite (Zn-HA). Methods: Zn-HA (2% and 6% Zn) was prepared and evaluated for the crystalline nature, chemical structure, and microstructure of hydroxyapatite (HA). Blank and 5-FU loaded alginate-gelatin-Zn-HA scaffolds were prepared and evaluated in terms of surface area, pore size, pore volume, and morphology using the gas adsorption technique and scanning electron microscopy (SEM). Cell attachment studies were also carried out on normal human cell line. The scaffolds were stored for one year at room temperature and evaluated for any changes in their physico-chemical properties as well as 5-FU release profile. Results: The results showed that increasing zinc content decreased HA particle size. The blank scaffolds showed higher surface area, pore volume values, and a less porous structure compared to the drug-loaded ones. The pore size increased after scaffolds soaking in cell-line medium due to the hydrogel-forming materials' biodegradability and drug release. Cell growth on the presoaked drug-loaded scaffolds was improved compared to blank scaffold. XRD, FTIR and 5-FU release profile indicated that the stored scaffolds did not show any physical or chemical changes. Conclusion: The prepared scaffolds showed promising results regarding cell attachment capability and long-term stability.
- 11 July 2025
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 20 (4) , 1-15
Open AccessPromising Alginate-Gelatin Scaffolds Containing 5-Fluorouracil and Reinforced with Zinc-Modified Hydroxyapatite: Cell Attachment and One-Year Stability Study
Purpose: The current study evaluated the cell attachment capability and long-term stability of 5-fluorouracil (5-FU) loaded alginate-gelatin scaffolds reinforced with zinc-doped hydroxyapatite (Zn-HA). Methods: Zn-HA (2% and 6% Zn) was prepared and evaluated for the crystalline nature, chemical structure, and microstructure of hydroxyapatite (HA). Blank and 5-FU loaded alginate-gelatin-Zn-HA scaffolds were prepared and evaluated in terms of surface area, pore size, pore volume, and morphology using the gas adsorption technique and scanning electron microscopy (SEM). Cell attachment studies were also carried out on normal human cell line. The scaffolds were stored for one year at room temperature and evaluated for any changes in their physico-chemical properties as well as 5-FU release profile. Results: The results showed that increasing zinc content decreased HA particle size. The blank scaffolds showed higher surface area, pore volume values, and a less porous structure compared to the drug-loaded ones. The pore size increased after scaffolds soaking in cell-line medium due to the hydrogel-forming materials' biodegradability and drug release. Cell growth on the presoaked drug-loaded scaffolds was improved compared to blank scaffold. XRD, FTIR and 5-FU release profile indicated that the stored scaffolds did not show any physical or chemical changes. Conclusion: The prepared scaffolds showed promising results regarding cell attachment capability and long-term stability.
- Open Access
- 26 July 2022
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 23 (6) , 1-10
Convolution- and Deconvolution-Based Approaches for Prediction of Pharmacokinetic Parameters of Diltiazem Extended-Release Products in Flow-Through Cell Dissolution Tester
The present study evaluated the effect of different configuration setups of the Flow-Through Cell (USP IV) dissolution tester in developing in vitro–in vivo correlation (IVIVC). A Biopharmaceutics Classification System (BCS) Class I Diltiazem (DTZ), formulated in extended-release (ER) gel-matrix system, was employed for this purpose. The study also assessed the validity and predictability of IVIVC employing both deconvolution- and convolution-based approaches. In vitro release was conducted in USP IV as open- or closed-loop setups, while the pharmacokinetic (PK) data were obtained from a previous fasted-state cross-over study conducted on 8 healthy male volunteers, after oral administration of ER matrix tablets against market product (Tildiem Retard® 90 mg). PK parameters (Cmax, AUC0-t and AUC0-∞) were predicted, and compared with actual data to establish the strength of correlation models. Results showed that DTZ release from ER products was influenced by operating the FTC in different configuration-setups, where ≥ 75% of labeled DTZ was released after 6 h and 12 h using the open- and closed-loop settings, respectively. Correlation between fraction-dissolved versus fraction-absorbed for both ER products displayed linear relation upon employing FTC open-loop setup. Convolution-based approach was more discriminative in predicting DTZ in vivo PK parameters with a minimal prediction error, compared to deconvolution-based approach. A successful trial to predict DTZ PKs from individual in vitro data performed in USP IV dissolution model was established, employing convolution technique. Basic principle of the convolution approach provides a simple and practical method for developing IVIVC, hence could be utilized for other BCS Class I extended-release drug products. Graphical abstract
- 26 July 2022
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 23 (6) , 1-10
Open AccessConvolution- and Deconvolution-Based Approaches for Prediction of Pharmacokinetic Parameters of Diltiazem Extended-Release Products in Flow-Through Cell Dissolution Tester
The present study evaluated the effect of different configuration setups of the Flow-Through Cell (USP IV) dissolution tester in developing in vitro–in vivo correlation (IVIVC). A Biopharmaceutics Classification System (BCS) Class I Diltiazem (DTZ), formulated in extended-release (ER) gel-matrix system, was employed for this purpose. The study also assessed the validity and predictability of IVIVC employing both deconvolution- and convolution-based approaches. In vitro release was conducted in USP IV as open- or closed-loop setups, while the pharmacokinetic (PK) data were obtained from a previous fasted-state cross-over study conducted on 8 healthy male volunteers, after oral administration of ER matrix tablets against market product (Tildiem Retard® 90 mg). PK parameters (Cmax, AUC0-t and AUC0-∞) were predicted, and compared with actual data to establish the strength of correlation models. Results showed that DTZ release from ER products was influenced by operating the FTC in different configuration-setups, where ≥ 75% of labeled DTZ was released after 6 h and 12 h using the open- and closed-loop settings, respectively. Correlation between fraction-dissolved versus fraction-absorbed for both ER products displayed linear relation upon employing FTC open-loop setup. Convolution-based approach was more discriminative in predicting DTZ in vivo PK parameters with a minimal prediction error, compared to deconvolution-based approach. A successful trial to predict DTZ PKs from individual in vitro data performed in USP IV dissolution model was established, employing convolution technique. Basic principle of the convolution approach provides a simple and practical method for developing IVIVC, hence could be utilized for other BCS Class I extended-release drug products. Graphical abstract
- 10 March 2021
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 17 (3) , 674-689
Modulating Gliclazide Release and Bioavailability Utilizing Multiparticulate Drug Delivery Systems
- 10 March 2021
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 17 (3) , 674-689
Modulating Gliclazide Release and Bioavailability Utilizing Multiparticulate Drug Delivery Systems
- 21 December 2020
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 47 (1) , 163-175
Preparation, characterization and in-Vitro/in-Vivo evaluation of meloxicam extruded pellets with enhanced bioavailability and stability
The present study involved enhancement of Meloxicam (MX) oral absorption for rapid onset of therapeutic action. A challenging approach using hot-melt-extrusion technique (HME) for production of sta...
- 21 December 2020
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 47 (1) , 163-175
Preparation, characterization and in-Vitro/in-Vivo evaluation of meloxicam extruded pellets with enhanced bioavailability and stability
The present study involved enhancement of Meloxicam (MX) oral absorption for rapid onset of therapeutic action. A challenging approach using hot-melt-extrusion technique (HME) for production of sta...
- 7 November 2020
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 11 (1) , 86-95
Biological and Mechanical Properties of Denture Base Material as a Vehicle for Novel Hydroxyapatite Nanoparticles Loaded with Drug
Purpose: This study aimed to evaluate the biological and mechanical properties of the poly(methyl methacrylate) (PMMA) denture base material as a vehicle incorporating novel hydroxyapatite nanoparticles (HA-NP) loaded with metronidazole (MZ) drug. Methods: HA-NP was prepared via wet-chemical-method, characterized by XRD, SEM/EDX, TEM, Fourier-transform infrared spectroscopy (FTIR), as well as the measurement of surface area and pore-size distribution. Four drug delivery formulas were prepared in the form of discs (10 x 2 mm) as follows: F1 (MZ/ HA-NP/PMMA), F2 (HA-NP/ PMMA), F3 (control-PMMA) and F4 (MZ/PMMA). Characterization of all formulas was performed using differential scanning calorimetry (DSC) and FTIR. MZ release rate, antimicrobial properties against three oral pathogens, cytotoxicity (MTT assay) and surface micro-hardness were also assessed. Statistical analysis of data was performed using one-way ANOVA test (P < 0.05). Results: DSC thermograms showed compatibility among MZ, HA-NP and PMMA along with physical stability over 6 months storage period at room temperature. FTIR spectroscopy proved the absence of any possible chemical interaction with MZ. MZ-HA-NP/PMMA formula showed relatively better drug release compared to MZ-PMMA. Both formulas showed statistically significant antimicrobial potentials against two microbial strains. MTT demonstrated reduction in cell cytotoxicity after 96 hours with the least value for HA-NP. Surface micro-hardness revealed non-significant reduction compared with the control PMMA. Conclusion: A novel biocompatible drug nanocarrier (HA-NP) was developed and incorporated in PMMA denture base material as a vehicle to allow prolonged sustained drug release to manage oral infections.
- 7 November 2020
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 11 (1) , 86-95
Biological and Mechanical Properties of Denture Base Material as a Vehicle for Novel Hydroxyapatite Nanoparticles Loaded with Drug
Purpose: This study aimed to evaluate the biological and mechanical properties of the poly(methyl methacrylate) (PMMA) denture base material as a vehicle incorporating novel hydroxyapatite nanoparticles (HA-NP) loaded with metronidazole (MZ) drug. Methods: HA-NP was prepared via wet-chemical-method, characterized by XRD, SEM/EDX, TEM, Fourier-transform infrared spectroscopy (FTIR), as well as the measurement of surface area and pore-size distribution. Four drug delivery formulas were prepared in the form of discs (10 x 2 mm) as follows: F1 (MZ/ HA-NP/PMMA), F2 (HA-NP/ PMMA), F3 (control-PMMA) and F4 (MZ/PMMA). Characterization of all formulas was performed using differential scanning calorimetry (DSC) and FTIR. MZ release rate, antimicrobial properties against three oral pathogens, cytotoxicity (MTT assay) and surface micro-hardness were also assessed. Statistical analysis of data was performed using one-way ANOVA test (P < 0.05). Results: DSC thermograms showed compatibility among MZ, HA-NP and PMMA along with physical stability over 6 months storage period at room temperature. FTIR spectroscopy proved the absence of any possible chemical interaction with MZ. MZ-HA-NP/PMMA formula showed relatively better drug release compared to MZ-PMMA. Both formulas showed statistically significant antimicrobial potentials against two microbial strains. MTT demonstrated reduction in cell cytotoxicity after 96 hours with the least value for HA-NP. Surface micro-hardness revealed non-significant reduction compared with the control PMMA. Conclusion: A novel biocompatible drug nanocarrier (HA-NP) was developed and incorporated in PMMA denture base material as a vehicle to allow prolonged sustained drug release to manage oral infections.
- 10 July 2020
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 46 (8) , 1362-1372
A novel combination of Soluplus®/Poloxamer for Meloxicam solid dispersions via hot melt extrusion for rapid onset of action. Part 2: comparative bioavailability and IVIVC
Objective: Bioavailability of Meloxicam (MLX) from solid dispersions (SDs), against innovator product Mobic® in humans was conducted. Furthermore, to establish a good in vitro-in vivo correlation (IVIVC); dissolution studies were carried-out in different media. Methods: MLX/SDs was prepared using Soluplus/Poloxamer via hot-melt-extrusion (EXT-SD) and fusion melt (FUS-SD) techniques. A single oral dose (15 mg), three periods, crossover study of MLX/SDs and Mobic® in 4 healthy humans under fed conditions was carried-out. In vitro dissolution was studied in pH 1.2, distilled water (pH 6.4) and biorelevant simulated gastric media in pre- and post-prandial states. Level A IVIVC was carried-out by comparing time-scaled fraction dissolved versus fraction absorbed, calculated using the Wagner-Nelson method. Multiple level C models were developed for Cmax and AUC0-96 versus % dissolved at different time-points. Internal predictability was evaluated for both IVIVC models. Results: MLX rate of absorption (Tmax) from EXT-SD, FUS-SD and Mobic® were 1.5, 3.0 and 4.0 h, respectively. Moreover, 1.45 - and 1.40 – folds increase in AUC0-∞ and Cmax, was obtained for EXT-SD versus Mobic®, respectively, while FUS-SD gave the lowest extent of drug absorption. EXT-SD provided highest dissolution profiles in all studied media. IVIVC models showed linear-regression (R2 ≥ 0.90) and prediction errors (≤ 10%) in water and post-prandial simulated gastric media. Conclusion: Hot-melt-extrusion technology promises an ideal alternative for enhancing MLX extent of absorption compared to Mobic® with Tmax value almost equal to the reported intramuscular injection. Predictive IVIVC was established for in vitro dissolution profile and in vivo performance.
- 10 July 2020
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 46 (8) , 1362-1372
A novel combination of Soluplus®/Poloxamer for Meloxicam solid dispersions via hot melt extrusion for rapid onset of action. Part 2: comparative bioavailability and IVIVC
Objective: Bioavailability of Meloxicam (MLX) from solid dispersions (SDs), against innovator product Mobic® in humans was conducted. Furthermore, to establish a good in vitro-in vivo correlation (IVIVC); dissolution studies were carried-out in different media. Methods: MLX/SDs was prepared using Soluplus/Poloxamer via hot-melt-extrusion (EXT-SD) and fusion melt (FUS-SD) techniques. A single oral dose (15 mg), three periods, crossover study of MLX/SDs and Mobic® in 4 healthy humans under fed conditions was carried-out. In vitro dissolution was studied in pH 1.2, distilled water (pH 6.4) and biorelevant simulated gastric media in pre- and post-prandial states. Level A IVIVC was carried-out by comparing time-scaled fraction dissolved versus fraction absorbed, calculated using the Wagner-Nelson method. Multiple level C models were developed for Cmax and AUC0-96 versus % dissolved at different time-points. Internal predictability was evaluated for both IVIVC models. Results: MLX rate of absorption (Tmax) from EXT-SD, FUS-SD and Mobic® were 1.5, 3.0 and 4.0 h, respectively. Moreover, 1.45 - and 1.40 – folds increase in AUC0-∞ and Cmax, was obtained for EXT-SD versus Mobic®, respectively, while FUS-SD gave the lowest extent of drug absorption. EXT-SD provided highest dissolution profiles in all studied media. IVIVC models showed linear-regression (R2 ≥ 0.90) and prediction errors (≤ 10%) in water and post-prandial simulated gastric media. Conclusion: Hot-melt-extrusion technology promises an ideal alternative for enhancing MLX extent of absorption compared to Mobic® with Tmax value almost equal to the reported intramuscular injection. Predictive IVIVC was established for in vitro dissolution profile and in vivo performance.
- 14 November 2019
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 45 (12) , 1959-1972
Optimization of gliclazide loaded alginate-gelatin beads employing central composite design
Objective: The aim of this study was to optimize the formulation of alginate-gelatin (AL-GL) beads containing gliclazide (GLZ) employing design of experiments (DOE). Significance: DOE enabled identification of the interaction between the studied factors, deep understanding of GLZ release pattern and acceleration of the optimization process. Methods: A three-factor, three-level face centered design was employed. The effects of GLZ content (GLZ%, X1), polymer ratio (AL:GL ratio, X2), crosslinker concentration (glutaraldehyde, GA%, X3), and their interaction on incorporation efficiency (IE) and release rate were studied. The optimized formulation was prepared using numerical optimization and evaluated by DSC, FT-IR, SEM and release rate studies. Results: Increasing GA% (X3) decreased IE (Y1) with the highest magnitude of effect among the studied factors. On the other hand, increasing alginate content in AL:GL ratio (X2) increased IE (Y1). The amount of GLZ released Q0.5h, Q2h(pH 1.2) and Q4h(pH 7.4) decreased by increasing GLZ% (X1) and AL:GL ratio (X2). Both drug content and AL:GL ratio appeared to affect water penetration into the gel matrix and drug release. Generally, there was a direct relationship between GA% (X3) and GLZ release in pH 1.2 (Q0.5h and Q2h). However, in pH 7.4 (Q4h), increasing GA% decreased GLZ release. In addition, increasing GA% caused deviation from zero-order release model. The actual responses of the optimized formulation were in close agreement with the predicted ones. Conclusion: The selected factors and their levels studied in the optimization design were useful for tailoring the anticipated formulation characteristics and GLZ release pattern.
- 14 November 2019
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 45 (12) , 1959-1972
Optimization of gliclazide loaded alginate-gelatin beads employing central composite design
Objective: The aim of this study was to optimize the formulation of alginate-gelatin (AL-GL) beads containing gliclazide (GLZ) employing design of experiments (DOE). Significance: DOE enabled identification of the interaction between the studied factors, deep understanding of GLZ release pattern and acceleration of the optimization process. Methods: A three-factor, three-level face centered design was employed. The effects of GLZ content (GLZ%, X1), polymer ratio (AL:GL ratio, X2), crosslinker concentration (glutaraldehyde, GA%, X3), and their interaction on incorporation efficiency (IE) and release rate were studied. The optimized formulation was prepared using numerical optimization and evaluated by DSC, FT-IR, SEM and release rate studies. Results: Increasing GA% (X3) decreased IE (Y1) with the highest magnitude of effect among the studied factors. On the other hand, increasing alginate content in AL:GL ratio (X2) increased IE (Y1). The amount of GLZ released Q0.5h, Q2h(pH 1.2) and Q4h(pH 7.4) decreased by increasing GLZ% (X1) and AL:GL ratio (X2). Both drug content and AL:GL ratio appeared to affect water penetration into the gel matrix and drug release. Generally, there was a direct relationship between GA% (X3) and GLZ release in pH 1.2 (Q0.5h and Q2h). However, in pH 7.4 (Q4h), increasing GA% decreased GLZ release. In addition, increasing GA% caused deviation from zero-order release model. The actual responses of the optimized formulation were in close agreement with the predicted ones. Conclusion: The selected factors and their levels studied in the optimization design were useful for tailoring the anticipated formulation characteristics and GLZ release pattern.
- Open Access
- 4 August 2019
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Pharmacy and Pharmaceutical Sciences
- p. 65-72
COMPARATIVE IN VITRO DISSOLUTION STUDY ON METFORMIN MARKET PRODUCTS USING DIFFERENT DISSOLUTION APPARATUSES
Objective: This study was proposed to evaluate and compare the in vitro dissolution profiles of six Metformin Hydrochloride (MH) market products. Methods: Different dissolution apparatuses (USP apparatus II, IV and beaker method) were used to evaluate the dissolution profiles (in phosphate buffer, pH 6.8) of two immediate release (IR) generic products of Metformin Hydrochloride (MH): Cidophage® 1000 mg (G1, Egyptian market) and Metformin arrow® 1000 mg (G2, French market) with respect to the reference products named Glucophage® 850 mg (R1, Egyptian market and R2, French market). In addition to a generic controlled-release (CR) product; Cidophage Retard® 850 mg (G3) versus the reference product; Glucophage XR® 1000 mg (R3) (both from Egyptian market). Dissolution efficiency (D. E.) and the similarity factor (f2) were calculated. Weight uniformity, hardness, tablet dimensions and MH content were measured. Results: Results of the three apparatuses showed that MH IR products studied (reference and generics) did not meet the 75% USP 30 specifications for MH dissolved at 30 min. For MH CR products, Glucophage XR® did not fulfill the USP release criteria, while Cidophage Retard® did. USP apparatus IV revealed the highest sensitivity and discriminative capability. Conclusion: Generally, MH IR generics (G1 and G2) might be interchangeable with the innovator product (Glucophage®). However, Cidophage Retard® might not be interchangeable with Glucophage XR®.
- 4 August 2019
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Pharmacy and Pharmaceutical Sciences
- p. 65-72
Open AccessCOMPARATIVE IN VITRO DISSOLUTION STUDY ON METFORMIN MARKET PRODUCTS USING DIFFERENT DISSOLUTION APPARATUSES
Objective: This study was proposed to evaluate and compare the in vitro dissolution profiles of six Metformin Hydrochloride (MH) market products. Methods: Different dissolution apparatuses (USP apparatus II, IV and beaker method) were used to evaluate the dissolution profiles (in phosphate buffer, pH 6.8) of two immediate release (IR) generic products of Metformin Hydrochloride (MH): Cidophage® 1000 mg (G1, Egyptian market) and Metformin arrow® 1000 mg (G2, French market) with respect to the reference products named Glucophage® 850 mg (R1, Egyptian market and R2, French market). In addition to a generic controlled-release (CR) product; Cidophage Retard® 850 mg (G3) versus the reference product; Glucophage XR® 1000 mg (R3) (both from Egyptian market). Dissolution efficiency (D. E.) and the similarity factor (f2) were calculated. Weight uniformity, hardness, tablet dimensions and MH content were measured. Results: Results of the three apparatuses showed that MH IR products studied (reference and generics) did not meet the 75% USP 30 specifications for MH dissolved at 30 min. For MH CR products, Glucophage XR® did not fulfill the USP release criteria, while Cidophage Retard® did. USP apparatus IV revealed the highest sensitivity and discriminative capability. Conclusion: Generally, MH IR generics (G1 and G2) might be interchangeable with the innovator product (Glucophage®). However, Cidophage Retard® might not be interchangeable with Glucophage XR®.
- 3 July 2017
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 23 (10) , 1057-1066
Stability and bioavailability of diltiazem/polyethylene oxide matrix tablets
The aim of this study was to prepare and evaluate in vitro and in vivo; Diltiazem-Hydrochloride (DTZ) in sustained-release matrix tablets. Stability of DTZ tablets prepared with polyethylene oxide (MWs 900 000, 4 000 000, and 8 000 000) with or without addition of electrolytes was carried-out for 1-month, under short-term storage at 40 °C/75% RH. Stability was evaluated by DTZ content, DSC and drug release using the Flow-Through Cell (USP # IV). The majority of stored tablets were stable for 1-month under short-term storage with respect to DTZ content and drug release. DSC curves of stored samples showed appearance of new exothermic peak after 1-month storage at 40 °C/75% RH, which was not observed after 5 years storage at room temperature. A selected formula was tested in vivo against reference product on eight healthy human volunteers. DTZ-plasma profiles were different between the two formulae. However, no statistically significant differences were detected between Cmax, AUC0–48 and AUC0–∞. The two products were therapeutically in-equivalent, as 90% confidence intervals “T/R” were 88.82–205.76, 91.40–139.94, and 93.73–134.97 for Cmax, AUC0–48 and AUC0–∞, respectively. This study highlighted possible differences observed between the two regimes frequently applied for stability testing.
- 3 July 2017
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 23 (10) , 1057-1066
Stability and bioavailability of diltiazem/polyethylene oxide matrix tablets
The aim of this study was to prepare and evaluate in vitro and in vivo; Diltiazem-Hydrochloride (DTZ) in sustained-release matrix tablets. Stability of DTZ tablets prepared with polyethylene oxide (MWs 900 000, 4 000 000, and 8 000 000) with or without addition of electrolytes was carried-out for 1-month, under short-term storage at 40 °C/75% RH. Stability was evaluated by DTZ content, DSC and drug release using the Flow-Through Cell (USP # IV). The majority of stored tablets were stable for 1-month under short-term storage with respect to DTZ content and drug release. DSC curves of stored samples showed appearance of new exothermic peak after 1-month storage at 40 °C/75% RH, which was not observed after 5 years storage at room temperature. A selected formula was tested in vivo against reference product on eight healthy human volunteers. DTZ-plasma profiles were different between the two formulae. However, no statistically significant differences were detected between Cmax, AUC0–48 and AUC0–∞. The two products were therapeutically in-equivalent, as 90% confidence intervals “T/R” were 88.82–205.76, 91.40–139.94, and 93.73–134.97 for Cmax, AUC0–48 and AUC0–∞, respectively. This study highlighted possible differences observed between the two regimes frequently applied for stability testing.
- Open Access
- 1 January 2017
- Published by Open Science Publishers LLP in Journal of Applied Pharmaceutical Science
- Vol. 7 (8) , 156-167
Hot melt extrusion method for preparation of ibuprofen/sucroester WE15 solid dispersions: evaluation and stability assessment
Low melting points Sucroesters (SEs) are used in hot-melt extrusion technology (HME). However, there are few literatures studying the effect of SEs on drug release and their storage stability. In this study, SE WE15 was proposed to prepare sustained-release solid dispersions with Iburpofen (IBU), containing 60 & 30% w/w, by HME, fusion method and compared to physical mixtures. The fresh and stored samples were evaluated by a well-established release rate study (USP Apparatus IV), DSC and XRD. Results revealed that HME technique succeeded to produce sustained-release patterns for IBU. Stored samples (6 months at 40C / 75 % RH) were unstable and showed gradual decrease in IBU release rate for both IBU loadings. HME formula (60% w/w IBU) showed an increase in the amount of drug released. Long term stability, one year at room temperature, showed a marked increase in IBU release rate for both drug loadings. Only HME containing 30% w/w IBU gave stable form among others. DSC and XRD suggested that increase of SE content led to almost complete IBU dissolved in this carrier, and considerable decrease in IBU release rate. This has been proven by DSC and XRD data analysis for IBU and SE (enthalpy and counts).
- 1 January 2017
- Published by Open Science Publishers LLP in Journal of Applied Pharmaceutical Science
- Vol. 7 (8) , 156-167
Open AccessHot melt extrusion method for preparation of ibuprofen/sucroester WE15 solid dispersions: evaluation and stability assessment
Low melting points Sucroesters (SEs) are used in hot-melt extrusion technology (HME). However, there are few literatures studying the effect of SEs on drug release and their storage stability. In this study, SE WE15 was proposed to prepare sustained-release solid dispersions with Iburpofen (IBU), containing 60 & 30% w/w, by HME, fusion method and compared to physical mixtures. The fresh and stored samples were evaluated by a well-established release rate study (USP Apparatus IV), DSC and XRD. Results revealed that HME technique succeeded to produce sustained-release patterns for IBU. Stored samples (6 months at 40C / 75 % RH) were unstable and showed gradual decrease in IBU release rate for both IBU loadings. HME formula (60% w/w IBU) showed an increase in the amount of drug released. Long term stability, one year at room temperature, showed a marked increase in IBU release rate for both drug loadings. Only HME containing 30% w/w IBU gave stable form among others. DSC and XRD suggested that increase of SE content led to almost complete IBU dissolved in this carrier, and considerable decrease in IBU release rate. This has been proven by DSC and XRD data analysis for IBU and SE (enthalpy and counts).